期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗血小板聚集药坎格雷洛研究进展 被引量：3

原文传递
导出
摘要 坎格雷洛(Cangrelor)是非噻吩并吡啶类嘌呤受体P2Y12的拮抗剂,作为一个快速作用的静脉注射抗血栓药物,用于治疗急性冠脉综合征。坎格雷洛目前正处于Ⅲ期临床开发阶段。对坎格雷洛的药理和临床研究作一概述。
作者 李树军 常淑梅 黄汉忠
机构地区 天津药物研究院化学制药研究部 天津生物化学制药有限公司
出处 《现代药物与临床》 CAS 2009年第6期327-330,共4页 Drugs & Clinic
关键词 坎格雷洛 嘌呤受体P2Y12拮抗剂 血小板聚集
分类号 R973.2 [医药卫生—药品]
  • 相关文献

参考文献23

  • 1Humphries R G, Tomlinson W, Clegg J A, et al, Pharmacological profile of the novel P2T purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo [J]. Br J Pharmacol,1995, 115(6): 1110-1116.
  • 2Fox S C, Behan M W, Heptinstall S. Inhibition of ADP induced intracellular Ca^2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931 MX and clopidogrel is enhanced by prostaglandin E1 [J]. Cell Calcium, 2004, 35(1): 39- 46.
  • 3Cattaneo M, Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostaeyclin [J]. J Thromh Haemost, 2007, 5 (3) : 577-582.
  • 4Kamae T, Shiraga M, Kashiwagi H, et al. Critical role of ADP interaction with P2Y12 receptor in the maintenance of αⅡBβ3 activation: Association with RaplB activation [J]. J Thromb Haemost,2006,4(6) : 1379-1387.
  • 5Van Giezen J J, Humphries R G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists [J]. SeminThromb Hemost, 200,5, 31 (2): 195-204.
  • 6Nylander S, Mattsson C, Ramstrom S, et al. The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin induced platelet activation [J]. Thromb Res,2003, 111 (1/2): 65-73.
  • 7Nylander S, Mattsson C, Ramstrom S, etal. Synergisticac tion between inhibition of P2Y12/P2Y1 and P2Y1/thrombin in ADP- and thrombin-induced human platelet activation[J]. Br J Pharmacol,2004, 142(8): 1325-1331.
  • 8Storey R F, May J A, Heptinstall S. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin[J]. Thromb Res,2005, 115(4): 301-307.
  • 9Goto S, Tamura N, Eto K, et al. Functional significance of adenosine 5'-diphosphate receptor (P2Y12) in platelet activa tion initiated by binding of yon Willebrand factor to platelet GP Ihα induced hy conditions of high shear rate [J]. Circulation,2002,105(21): 2531- 2536.
  • 10Turner N A, Moake J L, Mcintire L V. Blockade of adenosine diphosphate receptors P2Y12 and P2Y1 is required to in hibit platelet aggregation in whole blood under flow [J]. Blood,2001,98(12) : 3340-3345.

同被引文献80

  • 1乔德永,霍建丽,杨天雨,等.抗血栓生化药物的研究进展[J].药用生物技术,2009,16(5):477-480.
  • 2陈灏珠,林果为,王吉耀实用内科学[M].14版北京:人民卫生出版社:2013:9.
  • 3MICHOS ED,ARDEHALI R,BLUMENTHAL RS, et al. Aspirin and clopidogrel resistance [ C ~//Mayo Clinic Proceedings. Elsevier, 2006,81 (4) :518 -526.
  • 4ANGIOLILLO DJ, FERNANDEZ-ORTIZ A, BERNARDO E, et al. Variability in individual responsiveness to clopidogrel: clini- cal implications, management, and future perspectives[ J]. J Am College Cardiol, 2007,49 ( 14 ) : 1505 - 1516.
  • 5GEISLER T, GAWAZ M. Variable response to clopidogrel in pa- tients with coronary artery disease [ C ]//Seminars in thrombosis and hemostasis. 2007, 33 (2) : 196 - 202.
  • 6TAN GM, LAM YY, YAN BP. Novel platelet ADP P2Y12 in- hibitors in the treatment of acute coronary syndrome[ J]. Cardio- vasc Therap, 2012,30(4) : e167 -e173.
  • 7BRANDT JT, PAYNE CD, WIVIOTT SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite for- mation [ J~. Am Heart J, 2007,153 ( I ) :66. e9 - 66. el6.
  • 8SUGIDACHI A, OGAWA T, KURIHARA A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with simi- lar antiplatelet activity to that of clopidogrel's active metabolite [ J]. J Thrombos Haemostas, 2007,5(7) : 1545 -1551.
  • 9ROE MT, ARMSTRONG PW, FOX K AA, et al. Prasugrel ver- sus clopidogrel for acute coronary syndromes without revascular- ization[ J]. New Engl J Med, 2012, 367 (14) : 1297 - 1309.
  • 10ROE MT, GOODMAN SG, OHMAN EM, et al. Elderly patients with acute coronary syndromes managed without revascularization insights into the safety of long-term dual antiplatelet therapy withreduced-dose prasugrel vs. standard-dose clopidogrel[ J]. Circu- lation, 2013,128(8) :828 -833.

引证文献3

二级引证文献33

现代药物与临床
2009年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部